Daily Bulletin

The Conversation

  • Written by Merlin Thomas, Adjunct Professor of Preventive Medicine, Baker IDI Heart & Diabetes Institute

Metformin is the most widely used drug to treat type 2 diabetes globally. In Australia, approximately two-thirds of patients with type 2 diabetes are prescribed metformin, either alone or in combination with other pills, or with insulin injections.

Alongside diet and exercise, metformin is considered the first-choice drug to improve glucose control in type 2 diabetes.

Metformin hydrochloride is the scientific or generic name for the active ingredient in tablets sold in Australia under 40 different proprietary or brand names.

image History Metformin was originally developed from natural compounds found in the plant Galega officinalis, known as French lilac or goat’s rue. Synthetic biguanides were developed in the 1920s in Germany, but their use was limited due to side effects. During the 1940s, however, French physician Jean Sterne examined a new biguanide called dimethylbiguanide or metformin. At the time, it was being studied for the treatment of influenza, but Sterne recognised it had glucose-lowering properties. He proposed calling it glucophage, meaning glucose eater, a name with which it is still commercially associated today. Metformin has been used to treat diabetes since the late 1950s. It is now on the World Health Organisation’s List of Essential Medicines needed for a basic health care system. How does it work? Insulin suppresses the production of glucose by the liver. One reason glucose levels remain high in those with type 2 diabetes is due to insufficient insulin. The liver continues to inappropriately make large amounts of glucose, even when glucose levels are already high. image A French physician pioneered metformin for the treatment of diabetes and proposed calling it glucophage, meaning glucose eater. from shutterstock.com Metformin is able to reduce glucose production by the liver by approximately one-third, through mechanisms that remain to be fully understood. When taken as directed, it will reduce the HbA1c, a marker of glucose control, by approximately 0.5% to 1%. Who uses it? Metformin is only indicated for lowering glucose levels in people with type 2 diabetes. However, it is also used off-label (when medications are prescribed for conditions other than what they’ve been approved for) to treat women with polycystic ovarian syndrome (PCOS) where it can be effective in some cases. Metformin is not used to treat people with gestational diabetes or type 1 diabetes, who must take insulin injections as required to control their glucose levels. How is it used? To work effectively, most people will take two to three grams of metformin every day. To fit this much into a tablet, all medications containing metformin are the size of a small bullet and easily the biggest tablets people with type 2 diabetes will have to take. Most people take their metformin twice a day (morning and night), although extended release formulations also allow for once-daily dosing. Because metformin is most commonly used in combination with other glucose-lowering drugs to manage type 2 diabetes, fixed-dose combinations combining metformin with other oral glucose-lowering agents are also available. What are the side effects? The most commonly reported side effects from metformin are gastrointestinal disturbances, such as nausea, diarrhoea, cramping and flatulence. These effect around one in five people to some degree. Usually the symptoms are mild and seen when people use high doses, when first starting metformin or increasing doses. image Around one in five people taking metformin will experience side effects to some degree. Wikimedia Commons The likelihood of developing side effects can be reduced by starting off with low doses and increasing them gradually. It is also recommended to take metformin with or after meals to reduce the initial risk of side effects. But even despite these precautions, side effects prevent about 10% of people with type 2 diabetes from taking meformin. Metformin is associated with a rare but life-threatening condition known as lactic acidosis, where the body builds up too much lactic acid. This can be caused by factors such as heart, liver or kidney failure. There is still controversy over whether metformin is the cause of lactic acidosis or whether it exacerbates the condition. Unlike some other anti-diabetic medications, low blood-glucose levels are seldom observed when metformin is used on its own. Metformin also has the advantage over other agents in that it does not cause weight gain and in some people (especially women) with type 2 diabetes it may reduce their weight slightly. Because metformin is largely removed from the body by the kidneys, people with type 2 diabetes who have impaired kidney function will require lower doses to maintain safe levels and prevent side effects. How much does it cost Metformin is fully funded through the Pharmaceutical Benefits Scheme for use in people with type 2 diabetes, with a maximum consumer price of A$19.08. Drug interactions Metformin competes for clearance by the kidneys with drugs including digoxin (for heart rhythm problems) trimethoprim and vancomycin (antibiotics), ranitidine and cimetidine (for heartburn), nifedipine and furosemide (for blood pressure) which all have the potential to modestly increase metformin levels. In practice, metformin can be safely given in people taking these other agents with cautious observation. Controversies Metformin was not approved by the United States Federal Drug Agency (FDA) until late 1994. This was because one arm of a large clinical trial was stopped prematurely in 1971 when participants receiving a potent biguanide (known as phenformin) died more often and had an increased risk of lactic acidosis. It remains controversial as to whether metformin can be used to prevent diabetes as well as treat it. Some clinical trials have shown that metformin is at least as effective as diet and exercise for preventing diabetes in those at high risk of developing it. The requirement to always discontinue metformin in patients with renal impairment has also undergone a rethink in the last few years, as the risks of its use appear to be less than those associated with alternative therapies that expose patients to risk of hypoglycaemia, fluid retention or other side effects.

Authors: Merlin Thomas, Adjunct Professor of Preventive Medicine, Baker IDI Heart & Diabetes Institute

Read more http://theconversation.com/weekly-dose-metformin-the-diabetes-drug-developed-from-french-lilac-64430

Writers Wanted

I studied 5,000 phone images: objects were more popular than people, but women took way more selfies


Bad reactions to the COVID vaccine will be rare, but Australians deserve a proper compensation scheme


Pacific tourism is desperate for a vaccine and travel freedoms, but the industry must learn from this crisis


The Conversation


Prime Minister Interview with Ben Fordham, 2GB

BEN FORDHAM: Scott Morrison, good morning to you.    PRIME MINISTER: Good morning, Ben. How are you?    FORDHAM: Good. How many days have you got to go?   PRIME MINISTER: I've got another we...

Scott Morrison - avatar Scott Morrison

Prime Minister Interview with Kieran Gilbert, Sky News

KIERAN GILBERT: Kieran Gilbert here with you and the Prime Minister joins me. Prime Minister, thanks so much for your time.  PRIME MINISTER: G'day Kieran.  GILBERT: An assumption a vaccine is ...

Daily Bulletin - avatar Daily Bulletin

Did BLM Really Change the US Police Work?

The Black Lives Matter (BLM) movement has proven that the power of the state rests in the hands of the people it governs. Following the death of 46-year-old black American George Floyd in a case of ...

a Guest Writer - avatar a Guest Writer

Business News

Cybersecurity data means nothing to business leaders without context

Top business leaders are starting to realise the widespread impact a cyberattack can have on a business. Unfortunately, according to a study by Forrester Consulting commissioned by Tenable, some...

Scott McKinnel, ANZ Country Manager, Tenable - avatar Scott McKinnel, ANZ Country Manager, Tenable

InteliCare triple winner at prestigious national technology awards

InteliCare triple winner at prestigious national technology awards Intelicare wins each nominated category and takes out overall category at national technology 2020 iAwards. Company wins overal...

Media Release - avatar Media Release

Arriba Group Founder, Marcella Romero, wins CEO Magazine’s Managing Director of the Year

Founder and Managing Director of the Arriba Group, Marcella Romero, has won Managing Director of the Year at last night’s The CEO Magazine’s Executive of the Year Awards. The CEO Magazine's Ex...

Lanham Media - avatar Lanham Media

News Co Media Group

Content & Technology Connecting Global Audiences

More Information - Less Opinion